Ouster went public on the NYSE in March 2021 after it completed its business combination with Colonnade Acquisition Corp., a SPAC.
The Latest SPAC News and Rumors: September 21, 2022
by Marlena Haddad on 2022-09-21 at 11:35am
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.
Latest SPAC News: Cano Health buys Doctor’s Medical Center for $300M, Ouster lays off 10% of staff, and Coeptis enters license agreement with University of Pittsburgh
Cano Health buys Doctor’s Medical Center for $300M to cement its primary care business in Florida
Miami-based Cano Health announced today the acquisition of fellow primary care provider Doctor’s Medical Center in a bid to grow its Medicare, Medicaid and Affordable Care Act (ACA) exchange memberships in South Florida.
The deal closed July 2 and ran Cano Health $300 million, $250 million of which the company said was financed by new debt.
Cano Health—which just recently joined the public markets through a $4.4 billion special purpose acquisition company merger—runs value-based primary care centers and provides support to other primary care practices treating senior patients.
Ouster lays off 10% of staff
Ouster (NYSE:OUST) announced that it is reducing its headcount by approximately 10%, reducing spending across the business by over 15% and suspending sales of common stock through at-the-market. The changes are part of the company’s comprehensive cost reduction initiative.
As of December 2021, Ouster employed approximately 217 people on a full-time basis in the U.S. and 61 people full-time internationally, for a total of 278 employees. Ousters cuts could affect around 28 employees in the company.
Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a “Multi-Antigen” CAR T Technology
Coeptis Therapeutics, Inc. (OTC PINK: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer. Completion of the exclusive license agreement for SNAP-CAR follows Coeptis’ entry into an option agreement with the University of Pittsburgh announced in May 2022.
Bull Horn (NASDAQ:BHSE) entered into a definitive agreement to combine with biopharmaceutical company Coeptis in April.
READ
Recent Posts
by Nicholas Alan Clayton on 2025-07-02 at 12:13pm
McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...
by Nicholas Alan Clayton on 2025-07-02 at 8:29am
At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....
by Nicholas Alan Clayton on 2025-07-02 at 6:28am
EQV Ventures II (NASDAQ:EVACU) announced the pricing of its upsized $420 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EVACU”, Wednesday, July 2, 2025. The new SPAC plans to merge with an energy target involved in upstream exploration or production. EQV II’s management team is led by...
by Nicholas Alan Clayton on 2025-07-01 at 7:51pm
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
by Nicholas Alan Clayton on 2025-07-01 at 7:47pm
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....